Clinical Trials Logo

ROS1 Gene Rearrangement clinical trials

View clinical trials related to ROS1 Gene Rearrangement.

Filter by:
  • None
  • Page 1

NCT ID: NCT06315010 Not yet recruiting - NSCLC Clinical Trials

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

REPOSE
Start date: August 2024
Phase: Phase 2
Study type: Interventional

REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.

NCT ID: NCT04989322 Recruiting - Nsclc Clinical Trials

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Start date: October 5, 2021
Phase: Phase 2
Study type: Interventional

Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.

NCT ID: NCT04084717 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Start date: December 3, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer. Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.

NCT ID: NCT04005144 Terminated - Clinical trials for Lung Non-Small Cell Carcinoma

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Start date: February 25, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03608007 Recruiting - Lung Cancer Clinical Trials

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Start date: June 15, 2018
Phase: Phase 2
Study type: Interventional

To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).

NCT ID: NCT02321501 Active, not recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Start date: June 22, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ceritinib and everolimus in treating patients with solid tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic) or stage IIIB-IV non-small cell lung cancer. Ceritinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.